+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens

Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens

Antimicrobial Agents and ChemoTherapy 32(12): 1825-1829

The comparative pharmacokinetics and serum inhibitory effects of clindamycin were evaluated in six healthy male subjects given multiple-dose infusions of the following regimes in a crossover fashion: 600 mg every 6 h, 900 mg every 8 h, and 1,200 mg every 12 h. Serial blood samples were obtained after the last dose in each regimen and analyzed for clindamycin by a sensitive and specific high-performance liquid chromatography assay technique. Clindamycin pharmacokinetics were estimated by using noncompartmental methods, and serum inhibitory titers were serially determined against Bacteroides fragilis ATCC 25285 and evaluated by using area under the serum inhibitory curve (AUIC). Maximum and minimum concentrations in plasma averaged 12.2 .+-. 1.6 and 1.2 .+-. 0.6, 16.3, .+-. 4.0 and 0.9 .+-. 0.5, and 16.8 .+-. 2.5 and 0.4 .+-. 0.2 .mu.g/ml for the 600-, 900-, and 1,200-mg regimens. respectively. Clindamycin plasma clearance and elimination half-life averaged 23.3 .+-. 4.0 titers/h and 1.9 .+-. 0.4 h for the 600-mg regimen, 25.6 .+-. 8.2 liters/h and 2.1 .+-. 0.4 h for the 900-mg regimen, and 26.4 .+-. 4.7 liters/h and 2.1 .+-. 0.4 h for the 1,200-mg regimen. These results were not significantly different. Apparent volume of distribution increased significantly for the 1,200-mg regimen compared with the 600-mg regimen. Mean maximum reciprocal serum inhibitory titers were 96 .+-. 35, 101 .+-. 43, and 160 .+-. 78 for the 600-, 900-, and 1,200-mg regimens respectively. Minimum reciprocal serum inhibitory titers averaged 12 .+-. 4, 6 .+-. 3, and 5 .+-. 2 for the low-, medium-, and high-dose regimens, respectively. Mean AUIC increased roughly in proportion to dose. Similar daily values for the area under the concentration-time curve and for AUIC for each of the regimens suggest similar daily drug exposure and serum inhibitory activity. A regimen of 1,200 mg every 12 h may represent an alternative dosing strategy for clindamycin.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 007135834

Download citation: RISBibTeXText

PMID: 3245695

DOI: 10.1128/AAC.32.12.1825

Related references

Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics 34(4): 549-558, 2007

Serum pharmacokinetics of clindamycin hydrochloride in normal dogs when administered at two dosage regimens. Veterinary Dermatology 22(5): 429-435, 2012

Cost analysis of two clindamycin dosing regimens. Dicp 23(12): 980-983, 1989

Meta-analysis of parenteral clindamycin dosing regimens. Annals of PharmacoTherapy 29(9): 852-858, 1995

Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. Journal of ChemoTherapy 22(3): 175-178, 2010

Serum concentrations and ex vivo inhibitory/bactericidal activity of clindamycin after administration of two oral dosages. ChemoTherapy 43(4): 227-231, 1997

Pharmacokinetics in drug therapy III: Clindamycin dosage regimens for treatment of chronic osteomyelitis. American Journal of Hospital Pharmacy 34(9): 980-983, 1977

Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria. Malaria Journal 7: 225-225, 2009

In vivo antibacterial effects of tretinoin-clindamycin and clindamycin alone on Propionibacterium acnes with varying clindamycin minimum inhibitory. Journal of Drugs in Dermatology 11(12): 1434-1438, 2013

Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. Journal of Pharmaceutical Sciences 74(8): 876-879, 1985

Pharmacokinetics-pharmacodynamics of a novel COMT inhibitor during multiple dosing regimens. Clinical Pharmacology & Therapeutics 53(2): 180, 1993

Cefotaxime pharmacokinetic and serum inhibitory activity following intermittent and continuous infusion dosing. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 270, 1992

Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens. British Journal of Clinical Pharmacology 65(6): 871-878, 2008

Comparative activity of various antimicrobial agents against clindamycin-resistant and clindamycin-susceptible Bacteroides fragilis group strains. Abstracts of the General Meeting of the American Society for Microbiology 97(0): 145, 1997

The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Methods and Findings in Experimental and Clinical Pharmacology 26(10): 781-788, 2005